Latest News - Biogen
Top Corporates Hub
Biogen
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why
23.12.2025 03:12
In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the company was also removed from the Nasdaq-100 index. At the same time, mixed analyst views now center on how QALSODY’s data, Biogen’s Alzheimer’s drug Leqembi, and its emerging multiple sclerosis pipeline might reshape the company’s future earnings mix as it adapts to index removal. We’ll now...
Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound
18.12.2025 00:16
Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...
Analysts flag risks for Strategy at Nasdaq 100 index reshuffle
12.12.2025 09:53
Bitcoin hoarding giant Strategy may be at risk of being removed from the Nasdaq 100 index at its annual reshuffle on Friday, amid questions over its business model that have weighed on its share price, some analysts flagged this week. After a sizzling rally that pushed its market capitalization to a peak of $128 billion earlier this year, Strategy - which started out as software company MicroStrategy but pivoted to bitcoin investing in 2020 - was included last December under the index's technology sub-category. Strategy reported a net profit of $2.78 billion for the three months ended September 30, compared with a loss of $340.2 million a year earlier, mostly driven by an accounting change that allowed it to book gains on its bitcoin holdings.
Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential
11.12.2025 08:12
Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift reflects a cautiously constructive Street narrative that balances near term execution risks with growing confidence in longer term drivers such as Leqembi, the core neurology franchise, and late stage pipeline assets. Stay tuned to learn how you can track these evolving assumptions and the...
Does Biogen’s Recent Share Price Rebound Reflect Its True Value in 2025?
11.12.2025 07:10
If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the numbers are really saying. The stock has climbed 13.6% over the last month and is up 18.4% year to date, even though it is still down sharply over 3 and 5 years. That hints at a possible shift in how the market is reassessing its long term prospects and risk profile. Recent headlines have...
3 Healthcare Stocks We Think Twice About
11.12.2025 04:31
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 13.5%, nearly mirrorring the S&P 500.
Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.
08.12.2025 11:00
Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.
Is Biogen Stock Outperforming the Dow?
08.12.2025 08:37
Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.
1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds
08.12.2025 04:32
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
05.12.2025 14:00
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and c
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
05.12.2025 14:00
BEDFORD, Mass. & CAMBRIDGE, Mass., December 05, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
02.12.2025 06:00
INCHEON, Korea, December 02, 2025--Samsung Bioepis' Byooviz PFS gains European approval.
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
28.11.2025 00:30
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
20.11.2025 12:30
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at th
Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal
13.11.2025 08:00
AFPs promise to connect patients with more-affordable options for accessing specialty medications that often come at very high costs. There's a major catch.
Biogen Shares Recover Slightly Amid Clinical Trial Partnerships — Is the Stock Trading Below Fair Value?
07.11.2025 03:17
Wondering if Biogen stock is priced for opportunity or risk? You are not alone. There is a lot more beneath the surface to consider when assessing its true value. Recently, Biogen’s share price has seen a modest climb, up 4.8% over the past week and 3.0% in the last month. However, it is still down 9.9% over the past year, pointing to both shifting expectations and evolving market sentiment. Several headlines have caught investor attention, including new clinical trial partnerships and...
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
31.10.2025 14:15
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.
Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative
31.10.2025 11:16
Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%. Forecasts now call for earnings to grow at 7.3% per year, even as revenue is expected to decline at a 0.8% annual rate over the next three years. With shares trading at $149.61, well below the estimated fair value of $333.62 and a price-to-earnings ratio of 14.3x compared to the industry average of...
Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts
31.10.2025 04:25
Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest analysis for Biogen. While Biogen’s share price has dipped nearly 3% over the past month, the bigger picture shows momentum has faded, with a 90-day share price return of over 13% but a disappointing 1-year total shareholder return of -14%. That mix of short-term growth and long-term declines...
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
29.10.2025 03:09
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for.